Dronedarone hydrochloride has been used as an anti-arrhythmic drug to assess its impact in P19C5 embryoid bodies (EBs). It has also been used to determine its antiviral potency.
Biochem/physiol Actions
Dronedarone is a synthetic derivative of amiodarone, which belongs to the class of benzofurane anti-arrhythmic compounds. It might moderately block cytochrome P450 3A4 (CYP3A4) activity. Dronedarone is used to treat atrial flutter.
Dronedarone is a Class III antiarrhythmic and a multi-channel blocker for atrial fibrillation.
Dronedarone is a Class III antiarrhythmic and a multi-channel blocker for atrial fibrillation. It blocks potassium, sodium, and calcium channels and also exhibits antiadrenergic properties.
Features and Benefits
This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Atrial fibrillation (AF) is the most common sustained arrhythmia, affecting more than 2.2 million Americans. ACC/AHA/ESC guidelines for the management of patients with AF recommend amiodarone for maintaining sinus rhythm. Dronedarone is a derivative of amiodarone indicated for the treatment
Filovirus antiviral activity of cationic amphiphilic drugs is associated with lipophilicity and ability to induce phospholipidosis
Gunesch AP, et al.
Antimicrobial Agents and Chemotherapy (2020)
Use of in vitro morphogenesis of mouse embryoid bodies to assess developmental toxicity of therapeutic drugs contraindicated in pregnancy